A comparative study to evaluate the efficacy of asana bilwadi taila nasya and laghu soota shekhara rasa orally with shirish moola-beeja avapida nasya followed by go ghrita nasya and laghu soota shekhara rasa orally in the management of ardhavabhedaka W. S. R to migrane.
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- VAS scale,MIDAS questionnare,grading on the basis of improvement of symptoms
研究概览
简要总结
This is an open labelled randomised comparative human clinical trial to evaluate the efficacy of Asana bilwadi taila nasya and Shirish beeja-moola Avapida nasya ,where Laghu soota shikhara rasa (LSSR) will be given orally to both groups in the management of Ardhavabhedaka WSR to Migrane..
Subject selection will be done randomly from GAH ,according to inclusion and exclusion criteria.
Two groups of 20 subjects each will be given trial medicine.LSSR will be given 3 days prior to Nasya to ensure Deepana karma.from fourth day nasya(either taila shirovirechana or avapida nasya) both 6 drops each nostril will be given for 7 days followed by 7 days gap for three times.thus 3 days oral medicine alone,21 days nasya with oral medicine,21 days gap with oral medicine alone completes 45 days trial.
Followup will be done after 21 days.
Appropriate statistical analysis will be done to assure the result.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 盲法
- None
入排标准
- 年龄范围
- 18.00 Year(s) 至 50.00 Year(s)（—）
- 性别
- All
入选标准
- •Symptoms of migraine,ardha parshwa vedana,bhedatoda shoola,pakshat,dashahat akasmat vedana,photophobia,phonophobia,nausea,vomiting,vertigo,pain in manya-bhru-shankha-karna-akshi-lalaatardhe.
排除标准
- •Pregnant and lactating women.
- •Patient suffering from major disease eg; Thyroid dysfunction, Diabetic mellitus, Heart disease, Cancer etc.
- •Opthalmoplegic migraine, Hemiplegic Migrane, Retinal Migrane, Basilar Migrane, Intractable Migrane.Complicated migraine, Status migranous.
- •Secondary headache caused by Meningitis, Brain tumour, Encephalitis, Cervical spondylitis, refractive error and Glaucoma.
- •Any other systemic disorders which interfere with the cause of the treatment will be excluded.
结局指标
主要结局
VAS scale,MIDAS questionnare,grading on the basis of improvement of symptoms
时间窗: 45 days
次要结局
- increase in quality of life(45 days)
研究者
Sugandha Rawat
Dr BRKR Govt Ayurveda college and hospital